iConsensus

  This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 777397.  

Title

Integrated control and sensing platform for biopharmaceutical cultivation process high-throughput development and production

Concept

iConsensus will provide innovative analytical, hardware, software and high-throughput (HTP) solutions for the development, monitoring and control of mammalian cell cultivation process producing biopharmaceuticals. iConsensus will develop an analytical platform with on-line/at-line sensors and detection methods measuring multiple factors in the cell culture and the produced biopharmaceutical. Under advanced data management, the analytical platform will be integrated in new micro-bioreactors for HTP screening on one hand and in classical stirred tank vessel bioreactor on the other hand. Based on the analytical information, feedback control will be applied. When deemed suitable, implementation in GMP production of the sensing and control tools will be carried on.

Participants

• Kungliga Tekniska Hoegskolan, Sweden (Coordinator)
• Université de Mons, Belgium
• PreSens Precision Sensing GmbH, Germany
• m2p-labs GmbH, Germany
• Universität Hohenheim, Germany
• Ipratech SA, Belgium
• Kantisto B.V., Netherlands
• IPRASENSE, France
• Micronit Microtechnologies B.V., Netherlands
• PAIA Biotech GmbH, Germany
• Svanholm.com ApS, Denmark
• Sanofi-Aventis Deutschland GmbH, Germany
• Bayer AG, Germany
• GlaxoSmithKline Research & Development Ltd.
• UCB Biopharma SPRL, Belgium
• Pfizer Ltd., United Kingdom
• Rentschler Biopharma SE, Germany
• Synthon Biopharmaceuticals B.V., Netherlands